Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

CRTX Stock: What to Know as Cortexyme Plummets 75%

Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint.

CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics

Today, CRDL stock is down despite very positive news of a Health Canada approval for a Phase 2 trial of the company's leading drug.

AGC Stock: 7 Things to Know About Altimeter Growth as Investors Bet on a Big Squeeze

Here's what's behind the recent rise of Altimeter Growth and AGC stock, as the company moves toward its upcoming SPAC merger.

Lidar Stocks: What Is Going on With VLDR, LAZR, LIDR, MVIS Stocks Today?

Today, a bullish analyst report on one of the various lidar stocks investors are watching took this sector higher before the late selloff.

MYSZ Stock Alert: The Huge Partnership News Sending Little-Known MySize Rocketing

Today, investors in measurement sizing technology company MySize are seeing interest explode, with MYSZ stock soaring 80%.